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ABSTRACT
Triple negative breast cancer (TNBC) is a highly metastatic disease that currently 
lacks effective prevention and treatment strategies. The insulin-like growth factor 
1 receptor (IGF1R) and focal adhesion kinase (FAK) signaling pathways function 
in numerous developmental processes, and alterations in both are linked with a 
number of common pathological diseases. Overexpression of IGF1R and FAK are 
closely associated with metastatic breast tumors. The present study investigated 
the interrelationship between IGF1R and FAK signaling in regulating the malignant 
properties of TNBC cells. Using small hairpin RNA (shRNA)-mediated IGF1R silencing 
methods, we showed that IGF1R is essential for sustaining mesenchymal morphologies 
of TNBC cells and modulates the expression of EMT-related markers. We further 
showed that IGF1R overexpression promotes migratory and invasive behaviors of TNBC 
cell lines. Most importantly, IGF1R-driven migration and invasion is predominantly 
mediated by FAK activation and can be suppressed using pharmacological inhibitors of 
FAK. Our findings in TNBC cells demonstrate a novel role of the IGF1R/FAK signaling 
pathway in regulating critical processes involved in the metastatic cascade. These 
results may improve the current understanding of the basic molecular mechanisms 
of TNBC metastasis and provide a strong rationale for co-targeting of IGF1R and FAK 
as therapy for mesenchymal TNBCs.
INTRODUCTION
Triple-negative breast cancers (TNBCs) are 
distinguished by the absence of estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth 
factor receptor 2 (HER2) expression and constitutes up 
to 20% of all breast cancers cases. TNBCs account for 
a disproportionate number of deaths from breast cancer, 
especially among premenopausal African-American and 
Hispanic women. High mortality rates among TNBC 
patients can partly be attributed to a propensity to develop 
distant metastases within 5-years of diagnosis, despite 
the use of systemic chemotherapy. The mechanisms 
underlying this propensity for metastases noted with 
TNBC remain poorly understood. Unlike other subtypes 
of breast cancer, there are currently no targeted agents 
approved to treat TNBCs, and the only option for patients 
is systemic chemotherapy with its inherent toxicities. 
Understanding mechanisms underlying the metastatic 
potential of TNBC can aid in the development of novel 
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therapies that reduce the number of deaths linked to this 
breast cancer subtype.
The IGF1R signaling cascade has received 
increased attention as a potential therapeutic target for 
breast cancers. Overexpression of IGF1R is common in 
breast carcinomas, and xenograft studies demonstrate 
that IGF1R up-regulation induces mammary tumor 
growth and metastases [1]. Furthermore, using genetic 
ablation of IGF1R expression in a basal-like breast 
cancer xenograft model, it has been shown that IGF1R 
is involved in breast tumorigenesis [2]. Elevated IGF1R 
levels appear to enhance cell survival and metastasis 
following chemotherapy, potentially leading to decreased 
survival for breast cancer patients [3]. Furthermore, 
phosphorylated IGF1R is detected in nearly 42% of 
TNBCs and is associated with poor survival [4]. There is 
some evidence showing differential effects of cytoplasmic 
IGF1R expression on disease-free survival (DFS) and 
breast cancer specific survival (BCSS) in ER-positive 
versus ER-negative breast cancers [5]. Elevated levels of 
IGF1R in ER-positive breast cancers correlated strongly 
with DFS and BCSS, whereas expression of IGF1R was 
associated with shorter DFS in TNBCs [5].
Several studies have provided new insights into 
the biological effects of insulin-like growth factor 1 
(IGF-1) ligand in epithelial to mesenchymal transition 
(EMT) in breast cancers [6–10]. For example, IGF-I 
induces the migration of breast cancer cells and increases 
the expression of genes involved in EMT [8, 9]. Taken 
together, these data suggest a key role for the IGF1R 
signaling axis in the metastatic nature of TNBCs 
and warrant further investigation into the molecular 
mechanisms regulated by IGF1R.
Given the importance of IGF1R signaling in 
carcinogenesis, a number of pharmacological antagonists 
have been developed. Several IGF1R/IR-specific small 
molecule inhibitors and human monoclonal antibodies 
are currently at various stages of preclinical and clinical 
investigation (reviewed in [11]). However, the majority of 
clinical trials have not produced encouraging results to date. 
This may be because available agents do not effectively 
inhibit IGF1R signaling or because of compensatory 
mechanisms that negate the effects of single therapies.
Focal adhesion kinase (FAK) is a cytoplasmic non-
receptor tyrosine kinase whose activation by integrins 
leads to activation of signaling mechanisms that promote 
tumorigenesis. Increased FAK activity has been detected 
in several invasive and metastatic cancer tissues, including 
breast, thyroid, prostate, and head and neck tumors, but is 
undetectable in normal and benign tumor tissues [12–16]. 
FAK gene amplification and overexpression has been 
demonstrated in primary and invasive metastatic breast 
cancers and may be a biomarker for invasive potential 
of breast tumors [17]. Several downstream signaling 
cascades have been shown to mediate FAK-induced cell 
migration, including Src and PI3K [18]. Cytoskeletal 
reorganization, cell motility, and local invasion of the 
host tissue are important factors in cancer metastasis. 
FAK plays a central role in regulating cell adhesion, 
polarity and motility by coordinating the spatiotemporal 
changes in the actin cytoskeleton and by activating Rac, 
Rho, and cdc42 GTPases [19–22], a family of proteins 
which are important regulators of cell polarity events like 
lamellipodia formation and Golgi reorientation.
Co-immunoprecipitation and degradation studies 
demonstrated that FAK directly binds to, stabilizes, and 
activates IGF1R in human cancer cells [23]. Zheng et 
al. demonstrated that the FERM domain of FAK directly 
binds to the β-subunit of IGF1R, which contains the 
tyrosine kinase domain [24]. Down-regulation of FAK 
results in degradation of IGF1R, and dual inhibition of 
FAK and IGF1R produces synergistic anti-tumor effects 
[25, 26]. Furthermore, co-inhibition of FAK and IGF1R 
decreased human glioma cell survival, increased cell 
detachment, and induced apoptosis via increased caspase-3 
and PARP cleavage [26]. Hence, we hypothesized that 
crosstalk between the IGF1R and FAK pathways may be 
a mechanism by which IGF1R affects EMT, invasion, and 
metastatic processes in TNBCs. Therefore, we sought to 
determine the precise roles of these molecules in TNBC 
migration and invasion of metastatic TNBC cell lines.
In this study, we specifically investigated the 
functions of IGF1R and FAK signaling and their 
involvement in the metastatic potential of human TNBCs. 
We show that IGF1R is a key regulator of EMT in human 
TNBC cells, and most interestingly, inhibition of IGF1R 
results in MET in TNBC cells of mesenchymal-like 
origin. Ablation of IGF1R results in decreased colony 
formation, migration, and invasion of TNBC cells. We 
further demonstrate that IGF1R mediates these processes 
in TNBC cells via the IGF1R/FAK signaling pathway. 
These observations demonstrate that IGF1R may promote 
TNBC metastasis in a FAK-dependent manner and 
provide a solid basis for exploring co-targeting IGF1R 
and FAK as a potential therapeutic approach in a subset of 
mesenchymal-like TNBCs.
RESULTS
IGF1R and FAK expression levels and validation 
of stable IGF1R knockdown in TNBC cells
Elevated expression of IGF1R was previously 
reported in tumor samples of patients with ER-negative 
breast cancers (5). To obtain evidence of expression in 
cultured TNBC cells, IGF1R and FAK protein levels were 
determined by Western blotting in a panel of mesenchymal 
human TNBC cell lines (MDA-MB-231, Hs578T, and 
BT-549) (Figure 1A). BT-549, MDA-MB-231, and 
Hs578T cells have been classified as MSL/M subtypes 
with mesenchymal characteristics [27]. Both MDA-
MB-231 and BT549 TNBC cells expressed IGF1R and 
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Figure 1: Stable silencing of IGF1R confers epithelial-like phenotypes in mesenchymal TNBC cells. (A) Endogenous 
expression of IGF1R-β and total FAK analyzed via Western blot analysis in a panel of mesenchymal human TNBC cells. (B) Western 
blot confirmation of stable lentiviral knockdown of IGF1R-α/β (IGF1R-KD) in MDA-MB-231 and BT549 TNBC cells. β-actin was used 
as a loading control. (C) Morphological changes in MDA-MB-231 and BT549 IGF1R-KD cells compared to EV control cells four to six 
passages post-lentiviral infections; brightfield magnification x20. (D) Western blot analyses of mesenchymal markers (vimentin, Snail-1, 
ZEB-1), motility marker pFAK, and epithelial markers (E-cadherin, claudin-1, and ZO-1) in cell lines stably expressing EV control plasmid 
or IGF1R-KD lentiviral plasmids using specific antibodies. β-actin was used as a loading control. (E) Relative mRNA expression levels 
of Vimentin, ZEB-1, and E-cadherin in MDA-MB-231 EV and IGF1R-KD cell lines was detected by TaqMan quantitative RT-PCR and 
normalized to RPLPO. The relative amounts of transcript were described using the 2–ΔΔCt method. Data are displayed in means ± standard 
deviation of at least three independent experiments of each group.
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FAK protein, while Hs578T cells expressed undetectable 
levels of both IGF1R and FAK protein (Figure 1A). 
To determine the role of IGF1R in TNBC cells, we 
established lentivirus-mediated stable TNBC anti-IGF1R-
α/β (IGF1R-KD) and empty vector (EV) control cell lines. 
Immunoblotting analysis showed that the expression level 
of IGF1R in MDA-MB-231/IGF1R-KD and BT549/
IGF1R-KD cells was reduced compared to EV control 
cells (Figure 1B), suggesting that lentivirus infection was 
highly efficient at inhibiting IGF1R expression.
Loss of IGF1R in mesenchymal TNBC cells 
promote epithelial-like phenotypes
Interestingly, we noted that knockdown of IGF1R 
induced mesenchymal to epithelial transition (MET) in 
TNBC cells displaying mesenchymal characteristics. 
Morphologically, MDA-MB-231 and BT549 EV control 
cells were spindle-shaped mesenchymal cells, whereas 
MDA-MB-231 and BT549 IGF1R-KD cells were 
tightly bound, rounded cells with epithelial phenotypes 
(Figure 1C). Moreover, these observations were confirmed 
by Western blotting using antibodies specific for EMT-
related markers, including mesenchymal (vimentin, 
Snail-1, and ZEB-1) and epithelial (E-cadherin, claudin-1, 
and ZO-1) markers. As shown in Figure 1D, consistent with 
their cobblestone-like, epithelial morphologies, vimentin, 
Snail-1, and ZEB-1 protein levels were down-regulated 
and E-cadherin, claudin-1, and ZO-1 protein expressions 
were up-regulated in IGF1R-KD cells compared to 
controls. Quantitative real-time PCR also revealed 
decreased mRNA expression of vimentin and ZEB-1 and 
increased expression of E-cadherin mRNA levels in stable 
MDA-MB-231 IGF1R-KD cells relative to EV controls 
(Figure 1E). Based on these morphologic changes shown 
in IGF1R-null cells, we concluded that IGF1R plays an 
essential role in inducing EMT-like phenotypes in TNBC 
cells, which renders them more motile and invasive.
Stable IGF1R inhibition suppresses TNBC cell 
colony formation, migration, and invasion
Cell migration and invasion are important hallmarks 
of malignant cells that contribute to metastatic phenotypes. 
In the present study, we assessed the effects of IGF1R 
inhibition on TNBC clonogenecity, cell migration, and 
invasion using colony formation, spheroid migration 
and Matrigel invasion assays, respectively. As expected, 
knockdown of IGF1R resulted in a significant decrease 
in colony growth of MDA-MB-231 (1.4-fold change; 
p = 0.042) and BT549 (4.4-fold change; p < 0.001) cells 
compared with EV control cells (Figure 2A). Because 
tumor spheroids mimic tumor migratory characteristics, 
we formed MDA-MB-231 and BT549 IGF1R-KD 
spheroids and compared these results to the EV control 
groups. Our results show a significantly higher radial 
migration patterns in EV controls as compared to 
IGF1R-KD cell lines (p < 0.001) (Figure 2B). These 
results clearly demonstrate the involvement of IGF1R 
in the migratory capabilities of TNBC cells. We next 
performed Matrigel invasion assays to examine the effects 
of IGF1R down-regulation on the invasive potential of 
TNBC cells. As evident from Figure 2C, IGF1R inhibition 
significantly decreased invasion of both MDA-MB-231 
and BT549 IGF1R-KD cells compared to EV control cells 
(p < 0.001). Collectively, these results show that IGF1R 
inhibition effectively inhibits colony formation, migration, 
and invasion of mesenchymal TNBC cells.
siRNA-mediated FAK down-regulation inhibits 
IGF1R expression and invasive potentials of 
TNBC cells
Previous studies have shown that FAK regulates 
IGF1R stability and auto-phosphorylation in several 
human cancer cells [23, 28]. Based on our observation that 
phosphorylated FAK levels were decreased in response to 
IGF1R silencing (Figure 1D), we sought to determine if 
FAK also regulated IGF1R activity in TNBC cell lines. 
We found that in both MDA-MB-231 and BT549 cells, 
siRNA-mediated FAK silencing resulted in decreased FAK 
expression and down-regulation of active and total IGF1R 
(Figures 3A and 3B). Further, we examined the effect of 
FAK silencing on in vitro cell invasion. Using Matrigel 
invasion assays, we found that MDA-MB-231 and BT549 
cells with transient FAK knockdown exhibited a significant 
reduction in invasion (p < 0.001) as compared with cells 
treated with control siRNA (Figure 3C). We further 
demonstrated that these observed effects on invasion 
were not the result of differences in proliferative potential 
(Figure 3D) or influences on cell survival (Figure 3E).
Effects of FAK-specific pharmacological 
inhibitors on expression of EMT markers, 
migration, and invasion in TNBC cells
Next, we tested the phosphorylation status of FAK 
and IGF1R in TNBC cells after treatments for 24 h with 
increasing concentrations with FAK-specific inhibitors, 
PF228 and PF878 (also known as VS-6063 and defactinib) 
(Figure 4A). In MDA-MB-231 and BT549 cells, both 
inhibitors led to dose-dependent dephosphorylation of FAK 
on residue Y397, as well as IGF1R dephosphorylation 
at Y1135/Y1136 (Figures 4B and 4C), with the more 
pronounced decrease being observed following treatment 
with 0.5–1.0 μM inhibitor for 24 h. Interestingly, we 
noted that both PF228 and PF878 caused a decrease in 
vimentin and an increase in E-cadherin protein expression 
in a concentration-dependent manner (Figure 4D) with no 
apparent effects on cell proliferation (Figure 4E) or cell 
survival under the same treatment conditions (Figure 4F). 
These data demonstrate a reciprocal regulation of IGF1R by 
FAK and further confirm our findings that the IGF1R/FAK 
signaling cascade is involved in TNBC cell EMT.
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Figure 2: Inhibition of IGF1R suppresses TNBC cell colony formation, migration, and invasion. (A) Colony formation 
assays using MDA-MB-231 and BT549 EV-control and IGF1R-KD cells; colonies counted contained at least > 50 cells/colony. Data are 
representative of the average of at least three independent experiments performed in triplicate. *p = 0.042 and ***p < 0.001 compared to EV 
control cells. (B) Evaluation of in vitro cell migration potentials of MDA-MB-231 and BT549 EV-control and IGF1R-KD cells by spheroid 
migration assay. Representative images (left, magnification x20) and the mean relative migration (±S.D.) in five different spheroids (right) 
are shown. ***p < 0.001 compared to EV control cells. (C) Representative images of cell invasion assays of MDA-MB-231 and BT549 EV 
control and IFG1R-KD cells plated in the upper chambers of Transwell units coated with Matrigel. Fetal bovine serum and fibronectin was 
used as chemo-attractants in the lower chambers. The results are expressed as the average number of invaded cells per field of view (means 
± S.D.; n = 6). ***p < 0.001 compared to EV control cells.
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Figure 3: Effects of FAK siRNA silencing on IGF1R expression, and cell invasion, proliferation, and survival. (A) 
Western blot analysis of FAK, pIGF1R, and total IGF1R protein levels in MDA-MB-231 and BT549 cells transiently transfected for 48 h 
with 50 nM of control siRNA, FAK siRNA-1, or FAK siRNA-2. β-actin was used as a loading control. The protein levels were confirmed 
in three independent experiments. (B) Quantified data of pIGF1R and total IGF1R protein levels, normalized to β-actin. Means and SDs 
of three separate experiments are shown. (C) Representative images of Transwell cell invasion assays of MDA-MB-231 and BT549 cells 
transiently transfected with 50 nM of control siRNA, FAK siRNA-1, or FAK siRNA-2. Pictures were taken at 20x magnification. The 
histograms show the average number of invasive cells (error bars represent S.D. of three independent experiments, each performed in 
replicates of five. **p < 0.01 and ***p < 0.001 compared to control siRNA transfected cells. (D) MDA-MB-231 and BT549 cells were 
transiently transfected with 50 nM of control siRNA, FAK siRNA-1, or FAK siRNA-2 as described above. After 48 h, cells were counted 
by trypan blue exclusion; data represented as a percentage of the control siRNA groups. The results represent the average of triplicated 
treatment groups performed at least three times with reproducible results. (E) Cell lines were transfected as described above for 48 h and 
cell survival was measured by SRB assays. The data represent mean growth inhibition compared to control siRNA treated cells for three 
independent experiments for each cell line.
Oncotarget4763www.impactjournals.com/oncotarget
Figure 4: Effects of FAK-specific inhibitors on IGF1R activity, invasion, and EMT-related protein expression in TNBC 
cells. (A) Chemical structures of two FAK tyrosine kinase inhibitors, PF-573228 and PF-04554878. The expression of pFAK, FAK, 
pIGF1R, and IGF1R were assessed via immunoblotting analysis in (B) MDA-MB-231 and (C) BT549 TNBC cells following treatments 
with indicated doses of PF228 and PF878 for 24 h. (D) Vimentin and E-cadherin expressions examined via Western blotting following 
treatments as indicated above. β-actin served as a loading control. (E) MDA-MB-231 and BT549 cells were treated with 0.5 μM PF228 
or 0.5 μM PF878 for 24 h. Cells were counted by trypan blue exclusion; data represented as a percentage of the vehicle treated (DMSO) 
control groups. The results represent the average of triplicated treatment groups performed at least three times with reproducible results. (F) 
Cell lines were treated with 0.5 μM PF228 or 0.5 μM PF878 for 24 h and the effects on cell survival was measured by SRB assays. The data 
represent mean growth inhibition compared to vehicle treated (DMSO) control cells for three independent experiments for each cell line.
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We performed spheroid migration assays to study 
whether FAK-specific tyrosine kinase inhibitors can 
influence migration of TNBC cells. MDA-MB-231 and 
BT549 spheroids grown in 96-well plates coated with 1% 
agarose were treated with vehicle control, 0.5 μM PF228, 
or 0.5 μM PF878. Twenty-four hours after treatments, the 
migrating capacity of control cells from spheroids was 
significantly higher than that of inhibitor-treated cells 
(p < 0.001) (Figure 5A). Furthermore, both FAK inhibitors 
significantly reduced the abilities of MDA-MB-231 and 
BT549 cell to invade across Matrigel-coated Boyden 
chambers (p < 0.001) (Figure 5B). Figure 5 demonstrates 
that phosphorylation of FAK at Y397 is decreased in a 
time-dependent manner in both cell lines, with a more 
pronounced decrease being observed following treatment 
with 0.5 μM PF228 or PF878 for 24 h. We also examined 
phosphorylated IGF1R levels in each cell line (Figures 
5C–5F). Similar to decreased FAK activity, active IGF1R 
levels reduced in a time-dependent manner in both cell 
lines. Both total FAK and IGF1R protein expression 
levels remained unchanged. Most notably, vimentin 
protein levels were also reduced in a time-dependent 
(Figures 5C and 5D) manner following pharmacologic 
inhibition. E-cadherin protein levels were increased 
while its transcriptional repressor, ZEB-1 was inversely 
decreased in inhibitor-treated cells compared to untreated 
control cells (Figures 5C and 5D). These results further 
indicate that a major effect of targeting FAK signaling in 
TNBC cells is the suppression of IGF1R activity, EMT, 
migration, and invasion.
FAK activation plays an essential role in IGF1R-
induced migration and invasion of TNBC cells
Recent studies have implicated FAK overexpression 
as an important factor in cancer migration, invasion and 
metastasis, including breast cancers [29, 30], but its 
precise mechanisms of action remain unclear. Intriguingly, 
we found that abrogation of IGF1R expression in MDA-
MB-231 and BT549 TNBC cells resulted in decreased 
FAK activation (Figure 1D). Although our findings clearly 
show the involvement of IGF1R in TNBC cell migration 
and invasion, we raised the question whether IGF1R-
dependent cell migration and invasion requires FAK 
protein. We prepared Hs578T cells stably transfected with 
EV-control (Hs578T-EV) or full-length IGF1R expression 
plasmid (Hs578T-IGF1R(+/+)) to test the potential 
requirement of FAK in IGF1R-mediated migration and 
invasion. Immunoblotting analyses revealed that IGF1R 
overexpression increased FAK activity and ZEB-1 
expression, which was accompanied by a decrease in the 
epithelial biomarkers E-cadherin and ZO-1 (Figure 6A). 
No observable changes were noted in vimentin expression, 
probably because these cells already express very high 
levels of the protein. Additionally, quantitative real-time 
PCR experiments showed that IGF1R overexpressing cells 
expressed lower E-cadherin and higher vimentin mRNA 
levels compared to IGF1R-null cells (Figure 6B).
We next analyzed the effects of FAK inhibition 
on IGF1R-mediated colony formation, migration, and 
invasive abilities of Hs578T-EV and IGF1R(+/+) cells 
using FAK-specific inhibitors, PF228 and PF878. In 
agreement with the absence of active FAK protein, 
Hs578T-EV cells were unresponsive to both PF228 and 
PF878 treatments; however, Hs578T-IGF1R(+/+) cells 
exhibited reduced clonogenecity following treatments 
with both inhibitors (Figure 6C). Likewise, FAK inhibitor 
treatments did not affect migration of IGF1R-null 
Hs578T cells, but IGF1R-overexpressing Hs578T cells 
displayed increased cell migration, which was inhibited 
in the presence of both FAK inhibitors (Figure 6D). 
Unlike IGF1R-null cells, which continued to invade 
in the presence of PF228 and PF878 inhibitors, IGF1R 
overexpression induced increased invasion of TNBC 
cells, which could also be effectively decreased by 
FAK inhibitors (Figure 6E). Inhibitor treatments had no 
observable effects on cell proliferation in either cell line 
(Figure 6F). Collectively, these results demonstrate that 
FAK is an integral molecule in mediating clonogenecity 
and the pro-migratory and pro-invasive effects of IGF1R 
in TNBC cells.
DISCUSSION
Multiple studies have implicated a role for IGF1R in 
breast cancer, including TNBC, and other malignancies; 
however, the specific molecular mechanisms underlying 
IGF1R’s involvement in TNBC are not fully understood. 
Our present study identifies a novel role for IGF1R 
signaling in the regulation of EMT and provides new 
insight into the downstream processes regulated by 
IGF1R in TNBC cells. This study is the first to show 
the cooperative effect of IGF1R and FAK signals in 
promoting malignant behaviors of TNBC cells. We 
propose a model of IGF1R/FAK crosstalk as one possible 
mechanism for regulating EMT, motility, and invasion in 
TNBC cells (Figure 7). A major finding from our study 
is that FAK-dependent IGF1R signaling is critical for 
maintaining mesenchymal morphologies and potentiating 
cell migration and invasion in TNBC cells. We found that 
inhibition of IGF1R induces changes resembling MET 
and decreases invasiveness in mesenchymal TNBC cells 
as evidenced by increased E-cadherin and decreased 
vimentin, ZEB1, and pFAK expression. Additionally, 
down-regulation of IGF1R significantly reduced colony 
number, invasive ability, and motility of TNBC cells, and 
ectopic expression of IGF1R produced opposite results.
Numerous cellular actions of the IGF-I/IGF1R 
signaling axis support its involvement in breast 
tumorigenesis, as it positively regulates cell survival, 
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Figure 5: FAK-specific inhibitors suppress spheroid migration, decrease IGF1R phosphorylation, and alter EMT-
marker expression levels in TNBC cells. (A) Spheroid cell migration assays were performed to analyze the migration potential of 
MDA-MB-231 and BT549 cells treated for 24 h with vehicle control (DMSO), 0.5 μM PF228 or 0.5 μM PF878. Representative images 
(left, magnification x10) and the mean relative migration (±S.D.) of five different spheroids (right) are shown. ***p < 0.001 compared to 
untreated control cells. (B) Transwell cell invasion assays of MDA-MB-231 and BT549 cells treated with vehicle control (DMSO), 0.5 μM 
PF228, or 0.5 μM PF878 for 24 h. The histograms show the average number of invasive cells (error bars represent S.D. of three independent 
experiments, each performed in replicates of five). ***p < 0.001 compared to control cells. Total protein lysates from (C) MDA-MB-231 
and (D) BT549 cells treated with vehicle control (DMSO), 0.5 μM PF228 or 0.5 μM PF878 for various time points (0, 30’, 1 h, 3 h, and 
24 h) were analyzed via Western blotting for expression of pFAK, FAK, pIGF1R, IGF1R, E-cadherin, vimentin, and ZEB-1. β-actin served 
as a loading control. Quantified data of pIGF1R and total IGF1R levels, normalized to β-actin for (E) MDA-MB-231 and (F) BT549 cells. 
Means and SDs of three separate experiments are shown.
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Figure 6: Inhibition of FAK abrogates IGF1R-mediated colony formation, migration, and invasion in TNBC 
cells. (A) Lysates of Hs578T TNBC cells stably expressing empty vector (EV) control or IGF1R-β expression plasmid (IGF1R +/+) 
were immunoblotted with specific antibodies for IGF1R-β, p-FAK, Vimentin, ZEB-1, E-cadherin, ZO-1, and β-actin loading control. (B) 
Relative mRNA expression levels of Vimentin and E-cadherin in EV and IGF1R(+/+) TNBC cell lines were detected as described above. 
Data are displayed in means ± S.D. of at least three independent experiments of each group. (C) Colony formation, (D) spheroid migration, 
and (E) Matrigel invasion assays were performed as described above on Hs578T TNBC cells expressing either empty vector (EV) control 
or overexpressing full-length IGF1R-β (IGF1R +/+) followed by treatments with DMSO (control), 0.5 μM PF228, or 0.5 μM PF878 for 
24 h. ***p < 0.001 compared to Hs578T-EV untreated controls; ###p < 0.001 compared to Hs578T-IGF1R(+/+) untreated cells. (F) Hs578T 
(EV) and Hs578T-IGF1R(+/+) cells were treated with 0.5 μM PF228 or 0.5 μM PF878 for 24 h and cells were counted by trypan blue 
exclusion. Data represented as a percentage of the vehicle treated (DMSO) control groups. The results represent the average of triplicated 
treatment groups performed at least three times with reproducible results.
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 anti-apoptotic properties, and cell migration. Evidence 
from in vitro studies suggests that IGF1R signaling has 
differential effects on biological processes in ER-positive 
compared to ER-negative breast tumors. For example, 
IGF-I induces mitogenic and anti-apoptotic responses 
in ER-positive MCF-7 breast cancer cells; however, in 
ER-negative MDA-MB-231 cells, IGF-1 only positively 
affects cell motility [31]. Immunohistochemical studies 
of invasive breast tumor tissues showed that nearly 42% 
of TNBC patient samples expressed markedly high active 
IGF1R/IR levels, which was suggested to be indicative 
of poor survival [4]. Taken together, these observations 
and our current findings suggest that certain cellular 
functions of IGF1R are vital for the metastatic spread of 
ER-negative breast cancer cells.
EMT-like processes facilitate tumor progression 
and cancer metastasis, which is supported by clinical data 
showing that EMT regulators correlate well with tumor 
aggressiveness and poor patient outcomes [32]. Elevated 
vimentin and reduced E-cadherin levels correlate with 
increased breast cancer cell migration, invasion, and 
malignant cancer phenotypes [33]. ER-negative breast 
tumors express higher levels of vimentin than ER-positive 
tumors and in vivo expression of vimentin correlates 
strongly with more malignant breast tumor phenotypes [34]. 
Others and we have shown that 50–75% of TNBC breast 
cancers express vimentin, which is associated with high 
tumor grade, ER-/PR- status, and chemo-resistance [35, 36]. 
In addition, Lehmann et al. identified two mesenchymal-
like subtypes of TNBCs [27], and another tissue-microarray 
based study examining 479 invasive breast carcinomas 
identified several EMT markers associated with basal-
like breast tumors [37]. Vimentin expression in TNBCs 
is associated with younger age and poor prognosis 
[36]. Collectively, these and our data demonstrate that 
mesenchymal-like TNBCs are common and may be 
particularly prone to EMT and metastatic recurrence.
Several transcriptional regulators of EMT, including 
members of the ZEB, Snail, and Twist families, negatively 
control E-cadherin expression. Mounting evidence 
suggests that malignant breast cancer cells undergo EMT, 
especially TNBC subtypes [38]. ZEB1 mRNA levels are 
Figure 7: Proposed model of IGF1R/FAK crosstalk in TNBC. IGF1R/FAK signaling increases expression of the mesenchymal 
markers (vimentin, ZEB-1, and Snail-1) and decreases expression of epithelial markers (E-cadherin, ZO-1, and claudin-1) with subsequent 
facilitation of EMT, leading to increased cell migration and invasion. The potential sites of therapeutic intervention are indicated and lead 
to decreased EMT, cell migration, and cell invasion.
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inversely associated with high-grade breast tumors and 
appear to be involved in tumor metastasis and poor patient 
survival [39]. Elevated ZEB1 expression has also been 
associated with metastatic pancreatic carcinomas [40]. Our 
findings are consistent with previous reports identifying 
ZEB1 as a downstream target of IGF1R, potentially 
assisting EMT processes in breast cancer cells [41–43].
Given the importance of IGF1R signaling in 
carcinogenesis, a number of IGF1R-specific pharmacological 
antagonists, including small molecule inhibitors and human 
monoclonal antibodies, are currently at various stages of 
preclinical and clinical investigations (reviewed in [11]). 
Available clinical trials have not produced encouraging results 
to date, perhaps because available agents do not effectively 
inhibit IGF1R signaling [44, 45]. Our findings indicate that 
IGF1R could be a unique molecular target, of particular 
relevance in mesenchymal TNBCs by demonstrating that 
IGF1R inhibition reduces the invasive characteristics of 
mesenchymal-like TNBC cell lines in vitro. These results 
provide the first characterization of the cellular effects of 
IGF1R/FAK inhibition on EMT in mesenchymal TNBC 
cells. Given the fact that a significant percentage of TNBCs 
express IGF1R, FAK, and mesenchymal markers [5, 36, 
46], we consider our findings to have potentially important 
clinical implications for TNBC patients with mesenchymal 
phenotypes and warrant future clinical investigations which 
dually target the IGF1R and FAK signaling cascades.
MATERIALS AND METHODS
Reagents
The pLKO.1-IGF1R-α/β short hairpin RNA 
(shRNA) plasmid and pLKO.1 empty vector plasmid 
(negative control) were purchased from Open Biosystems 
(Huntsville, AL, USA). The pBABE-bleo-neo empty 
vector (plasmid 1766) and pBABE-bleo-IGF1R full-length 
expression vector (plasmid 11212) were obtained from 
Addgene (Cambridge, MA, USA). Dr. Adam Marcus at the 
Winship Cancer Institute of Emory University provided 
the pCMV-dR8.2 and pCMV-VSV-G helper constructs. 
RIPA cell lysis buffer was from Cell Signaling Technology, 
Inc. (Beverly, MA, USA), and protease inhibitor cocktail 
and phosphatase inhibitors were purchased from Sigma 
(Saint Louis, MO, USA). Puromycin was obtained 
from Invitrogen. PF573228 (PF228) was commercially 
available from Santa Cruz BioTechnology (Dallas, TX, 
USA) and PF04554878 (PF878) was generously provided 
by Dr. Adam Marcus. Matrigel and zeocin were purchased 
from BD Biosciences and agarose was from (Bio-Rad, 
Hercules, CA, USA).
Cell culture
MDA-MB-231, BT549, and Hs578T cell lines 
were obtained from American Type Culture Collection 
(Manassas, VA, USA). Dr. Rita Nahta at the Winship 
Cancer Institute of Emory University generously provided 
the HEK-293T packaging cell line. These cell lines were 
not authenticated. Cells were routinely maintained in 
Dulbecco’s Modification of Eagle’s Medium (DMEM) 
supplemented with 10% Fetal Bovine Serum (FBS) and 
2 μM L-glutamine (Invitrogen, Carlsbad, CA, USA).
Lentivirus preparation
1.5x106 HEK-293T cells were seeded in 100 mm 
dishes for 24 h and co-transfected with 3 μg shRNA 
constructs (pLKO.1-IGF1R-α/β shRNA (KD) or pLKO.1 
empty vector (EV) control plasmids), 3 μg pCMV-dR8.2, 
and 0.3 μg pCMV-VSV-G helper constructs using TransIT-
LT-1 Transfection reagent according to the manufacturer’s 
instructions (Mirus Bio LLC, Madison, WI, USA). 
Forty-eight hours after transfections, viral stocks were 
harvested from culture media by centrifugation to remove 
cells and syringe-filtered. TNBC cell lines were seeded 
at sub-confluent densities and infected with lentiviruses 
(1:20 dilution) in fresh culture media. Culture media was 
replaced with media containing 2-μg/ml puromycin 48 
hours after lentivirus infection to select for cells stably 
expressing the shRNAs (IGF1R-KD) or EV control 
plasmid. Stable clones were harvested after several 
passages for use and/or cryopreservation in liquid 
nitrogen.
siRNA transient transfections
siRNA was used to silence the FAK gene. FAK siRNA: 
FAK siRNA-1, 5′-GUAUUGGACCUGCGAGGGA-3′ 
(sense) and 5′-UCCCUCGCAGGUCCAAUAC-3′ 
(antisense); FAK siRNA-2, 5′-CGAAUGAUAAGGUGU 
ACGA-3′ (sense) and 5′-UCGUACACCUUAUCAUU 
CG-3′ (antisense) were commercially available from Sigma-
Aldrich (St Louis, MO, USA). A scrambled sequence 
siRNA (Control siRNA) was also used as a negative control 
(Sigma-Aldrich). Transit-TKO transfection reagent (Mirus 
Bio LLC, Madison, Wisconsin, USA) was used to optimize 
siRNA transfection according to the manufacturer’s 
instructions. Briefly, Transit-TKO and siRNA were diluted 
separately in serum-free Opti-MEM media (Gibco) and 
incubated for 5 min at room temperature. The two solutions 
were gently mixed and incubated together for 30 min at 
room temperature. After incubation, the complex was added 
to the plated cells. Forty-eight hours post transfection, 
cells were further assayed in colony formation, spheroid 
migration, and Matrigel invasion assays as detailed below.
Western blotting
Following treatments, total cell lysates were 
prepared using previously described methods [47]. 
Primary antibodies against pIGF1R (Tyr1135/1136), 
IGF1R-β, Snail-1, claudin-1, and ZO-1 were from Cell 
Signaling Technology, Inc. (Beverly, MA, USA). ZEB-1 
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antibody was from Santa Cruz Biotechnology, Inc. 
Antibodies against β-actin, and vimentin purchased from 
Sigma (Saint Louis, MO, USA) and pFAK (Tyr397), total 
FAK, and E-cadherin from BD Biosciences were used 
for Western blots according to standard protocol. Bound 
primary antibodies were detected with peroxidase-coupled 
secondary antibodies (Southern BioTech; Birmingham, 
AL, USA) and developed by enhanced chemiluminescence 
(Luminata Classico Western HRP substrate; EMD 
Millipore Corp.; Billerica, MA, USA).
Real-time RT-PCR
Total RNA was extracted using the RNeasy 
purification kit (Qiagen, Valencia, CA 91355) and treated 
with DNase (Invitrogen). cDNA was prepared from 
total RNA using random primers and the Superscript III 
first strand synthesis Kit (Invitrogen). Relative levels of 
mRNA were determined by real-time quantitative PCR 
using an Eppendorf cycler and the TaqMan Universal 
PCR master Mix (Applied Biosystems, Carlsbad, CA). 
Primers for Vimentin (Hs00185584_m1), ZEB-1 (Hs-
00232783_m1), E-cadherin (Hs01023894_m1), and 
RPLPO (Hs99999902_m1) were obtained from Applied 
Biosystems (TaqMan Gene Expression Assays). Samples 
were normalized against the RPLPO internal control using 
the 2–ΔΔCt method, compared as arbitrary units, and 
represented as mean ± SD. Samples were performed in 
triplicate and experiments were repeated at least 3 times 
with reproducible results.
Colony formation assay
Single cell-suspensions were seeded in 12-well 
plates (250 cells/well) and allowed to grow. After 10 days, 
colonies (< 50 cells/colony) were fixed in 10% methanol 
and stained with crystal violet (0.1% in 20% methanol). 
Pictures were acquired using an Olympus Arcturus 
microscope (Mountain View, CA, USA), Infinity-2 
Analyze digital camera, and software (Lumenera Corp., 
Ottawa, ON, Canada).
Matrigel invasion chamber assay
Invasion assays were performed using Transwell 
chambers with 8-μm pore polycarbonate membrane 
inserts (Corning Inc., Corning, NY, USA). 50,000 cells/
well were plated onto the upper chambers Matrigel-
coated inserts and allowed to invade for 24 hours. Fetal 
bovine serum and fibronectin were used in the lower 
chambers as chemoattractants. Non-invading cells were 
removed and invaded cells in the membrane were fixed 
in methanol, washed, and stained with 0.1% crystal 
violet. Inserts were washed, briefly air-dried, and 
mounted. Invaded cells were counted using an inverted 
microscope (20X magnification). Five fields were 
counted for each sample.
Spheroid migration assay
For migration assays, 2.0 × 104 cells suspended 
in complete medium containing 2.5% reconstituted 
basement membrane (rBM, Matrigel) were seeded onto 
1.0% agar-coated 96-well plates and cultured for 48 hours 
in a humidified atmosphere containing 5% CO2 at 37°C. 
Intact tumor spheroids were carefully transferred to six-
well plates and cultured in complete media for 24–48 
hours. Spheroids and migrated cells were fixed with 10% 
buffered formalin, stained with 0.05% crystal violet, 
and observed using a normal light microscope (20X) 
and Olympus DP-30BW digital camera. The distance of 
migration from the center of the spheroid was quantified 
using Image Pro software and is representative of three 
independent experiments, each performed in triplicate.
Stable overexpression of IGF1R
Human Hs578T TNBC cells were grown to 70% 
confluency and transfected with 3.0 μg control plasmid 
(pBABE-bleo) or IGF1R expression vector (pBABE-bleo-
IGF1R) using Transit-LTI according to manufacturer’s 
instructions. Forty-eight hours post transfection, culture 
media was refreshed with media containing 100 μg/ml of 
zeocin antibiotic to select for clones stably expressing the 
control vector and IGF1R expression vector. Stable cell 
lines were used for subsequent Western blotting analyses, 
colony formation, spheroid migration, and Matrigel 
invasion assays as described above.
Trypan blue exclusion
For growth inhibition assays, cells were plated in 
complete DMEM at 2 × 104 cells/per well in 12-well 
plates. The next day, media were aspirated and replaced 
with media containing vehicle control or FAK inhibitors 
in triplicate. After 24 h, viable cells were counted under a 
light microscope by trypan blue exclusion. Assays were 
repeated at least three times with reproducible results.
Cell survival assay
Cells were seeded at a density of 5000 cells/well in 
96-well plates and grown overnight before treatment with 
control and FAK siRNAs or indicated concentrations of 
PF228 and PF878 in complete culture media for 24 hours. 
Cell viability was assessed using sulforhodamine-B (SRB) 
assays following procedures previously described (27).
Statistical analysis
Quantitative data from in vitro experiments are 
presented as mean ± SD of experiments repeated at least 
three times in triplicate. Differences among group means 
were analyzed using one-way ANOVA or unpaired Student’s 
t-test. Differences were considered significant at p < 0.05.
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